<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04162314</url>
  </required_header>
  <id_info>
    <org_study_id>19-08-1046</org_study_id>
    <nct_id>NCT04162314</nct_id>
  </id_info>
  <brief_title>Beta-1,3/1,6-D-Glucan Ganoderma Lucidum on Non-infectious and Idiopathic Uveitis</brief_title>
  <official_title>The Role of Î²-1,3/1,6-D-Glucan From Extract of Indonesian Ganoderma Lucidum Mycelium as a Combination Therapy With Methylprednisolone for Treatment of Non-infectious and Idiopathic Uveitis: A Double-blind Randomized Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fakultas Kedokteran Universitas Indonesia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fakultas Kedokteran Universitas Indonesia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the effect of Beta-1,3/1,6-D-Glucan from mycelium extract of Indonesian
      Ganoderma lucidum as an adjuvant to methylprednisolone for non-infectious and idiopathic
      uveitis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with non-infectious and idiopathic uveitis will receive standard treatment with
      methylprednisolone, but will be randomized to receive either Beta-1,3/1,6-D-Glucan from
      mycelium extract of Indonesian Ganoderma lucidum or placebo. Follow up will be performed on
      week-2, week-4, week-6, month-2, and month-3. Outcomes measured are anterior chamber cells,
      visual acuity, and serum TNF-alpha levels.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2020</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in anterior chamber inflammatory cells grading</measure>
    <time_frame>Baseline, week-2, week-4, week-6, month-2, month-3</time_frame>
    <description>Change in anterior chamber inflammatory cells grading according to SUN nomenclature (0, 0.5+, 1+, 2+, 3+, 4+). 0 is minimum value (better outcome) and +4 is maximum value (worse outcome).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of serum TNF-alpha level</measure>
    <time_frame>Baseline, week-6, month-3</time_frame>
    <description>Change of serum TNF-alpha level</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Uveitis</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group received combination of mycelium extract of Ganoderma lucidum capsule containing 180 mg Beta-1,3/1,6-D-Glucan with 3x1 dosage and methylprednisolone (0.8 mg/kgBW) 1x1 for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group received combination of placebo capsules with 3x1 dosage and methylprednisolone (0.8 mg/kgBW) 1x1 for 90 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beta-1,3/1,6-D-Glucan Ganoderma lucidum</intervention_name>
    <description>Beta-1,3/1,6-D-Glucan capsule three times daily for 90 days</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>PsP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebos</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with non-infectious and idiopathic uveitis.

          2. Indicated to receive oral steroid and have signs of anterior segment inflammation.

          3. Anterior chamber inflammation &gt;= +2 according to SUN criteria.

          4. Age between 18 and 65 years old, good general condition, consented to be involved in
             the research, and are willing to come regularly according to follow up schedule.

        Exclusion Criteria:

          1. Received systemic steroid and/other immunosuppressive drugs two weeks before the start
             of the trial.

          2. Received antibiotics one week before the start of the trial.

          3. Contraindicated to oral steroid.

          4. Other primary ocular disorder, such as glaucoma, anterior segment dysgenesis, or
             others.

          5. Pregnant and nursing women.

          6. Patients with history of hypersensitivity/ allergy to Ganoderma species or other
             fungi.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lukman Edwar, SpM(K), Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>FKUI/RSCM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hasiana Lumban Gaol, MD</last_name>
    <phone>817200249</phone>
    <phone_ext>+62</phone_ext>
    <email>hasiana.lumbangaol@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lukman Edwar, SpM(K), Dr</last_name>
    <phone>811845804</phone>
    <phone_ext>+62</phone_ext>
    <email>lukmanedwar@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>RSCM Kirana</name>
      <address>
        <city>Jakarta Pusat</city>
        <state>DKI Jakarta</state>
        <zip>10320</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hasiana Lumban Gaol, MD</last_name>
      <phone>+62817200249</phone>
      <email>hasiana.lumbangaol@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 6, 2019</study_first_submitted>
  <study_first_submitted_qc>November 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2019</study_first_posted>
  <last_update_submitted>February 6, 2020</last_update_submitted>
  <last_update_submitted_qc>February 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fakultas Kedokteran Universitas Indonesia</investigator_affiliation>
    <investigator_full_name>Hasianalumban</investigator_full_name>
    <investigator_title>Ophthalmology resident</investigator_title>
  </responsible_party>
  <keyword>non-infectious uveitis</keyword>
  <keyword>idiopathic uveitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

